Get the Stockscreener App
2.04
0.00%
0.00
Relmada Therapeutics Inc stock is traded at $2.04, with a volume of 64,255.
It is up +0.00% in the last 24 hours and up +28.30% over the past month.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
See More
Previous Close:
$2.04
Open:
$2.05
24h Volume:
64,255
Relative Volume:
0.09
Market Cap:
$65.39M
Revenue:
-
Net Income/Loss:
$-98.79M
P/E Ratio:
-0.6239
EPS:
-3.27
Net Cash Flow:
$-51.66M
1W Performance:
-1.92%
1M Performance:
+28.30%
6M Performance:
+590.36%
1Y Performance:
-38.37%
1-Day Range:
$1.96
$2.08
1-Week Range:
$1.92
$2.27
52-Week Range:
$0.2404
$3.98
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Name
Relmada Therapeutics Inc
Sector
Industry
Phone
646 876 3459
Address
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
4.90 | 5.31B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
19.88 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.445 | 113.25M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.2077 | 445.05M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
0.92 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
| Jun-05-24 | Downgrade | Goldman | Neutral → Sell |
| Oct-14-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-14-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-14-22 | Downgrade | Truist | Buy → Hold |
| Oct-13-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-18-21 | Initiated | Mizuho | Buy |
| May-20-21 | Resumed | Goldman | Buy |
| Oct-28-20 | Downgrade | Goldman | Buy → Neutral |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-04-20 | Initiated | SunTrust | Buy |
| Apr-21-20 | Initiated | Goldman | Buy |
| Jan-27-20 | Initiated | Jefferies | Buy |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-16-19 | Initiated | Guggenheim | Buy |
View All
Relmada Therapeutics Inc Stock (RLMD) Latest News
Will Relmada Therapeutics Inc. stock recover faster than marketPortfolio Risk Report & Free Long-Term Investment Growth Plans - newser.com
Combining machine learning predictions for Relmada Therapeutics Inc.Market Performance Recap & Stock Timing and Entry Methods - newser.com
Relmada seeking strategic options, stock climbs 5% - MSN
Relmada Therapeutics (NASDAQ:RLMD) Upgraded at Wall Street Zen - MarketBeat
D pipelineWeekly Trend Summary & High Return Trade Opportunity Guides - newser.com
Weiss Ratings Reiterates Sell (D-) Rating for Relmada Therapeutics (NASDAQ:RLMD) - MarketBeat
Relmada appoints Johns Hopkins professor to clinical advisory board - Investing.com
Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01 - Investing News Network
Relmada Therapeutics, Inc. Appoints Distinguished Urologic Oncologist, Max Kates, Md, to the Clinical Advisory Board - MarketScreener
Relmada appoints Johns Hopkins professor to clinical advisory board By Investing.com - Investing.com Australia
Relmada Therapeutics appoints Max Kates, MD, to the clinical advisory board to support development of NDV-01 - MarketScreener
Relmada Therapeutics Appoints Dr. Max Kates to Clinical Advisory Board to Support NDV-01 Phase 3 Program for Bladder Cancer - Quiver Quantitative
Phase 3 H1 2026 — Relmada Taps Max Kates to Guide NDV-01 for NMIBC, Bringing BRIDGE Trial Expertise - Stock Titan
Why Relmada Therapeutics Inc. stock is trending among retail tradersMarket Sentiment Summary & Verified Technical Trade Signals - newser.com
Using data tools to time your Relmada Therapeutics Inc. exit2025 Trading Recap & Weekly Watchlist for Hot Stocks - newser.com
Is Relmada Therapeutics Inc. (4E2) stock undervalued at current pricePortfolio Update Report & Low Drawdown Investment Strategies - newser.com
Earnings visualization tools for Relmada Therapeutics Inc.July 2025 Market Mood & Technical Pattern Recognition Alerts - newser.com
Relmada Therapeutics Inc. stock retracement – recovery analysis2025 Retail Activity & Precise Swing Trade Entry Alerts - newser.com
Using data filters to optimize entry into Relmada Therapeutics Inc.July 2025 Price Swings & Free Expert Approved Momentum Trade Ideas - newser.com
What drives Relmada Therapeutics Inc stock priceBlue Chip Stock Analysis & Investment Timing Techniques - earlytimes.in
Promising Penny Stocks To Watch In October 2025 - Yahoo Finance
Goldman Sachs Group Inc. Invests $33,000 in Relmada Therapeutics, Inc. $RLMD - Defense World
Using Python tools to backtest Relmada Therapeutics Inc. strategiesEarnings Beat & High Accuracy Swing Trade Signals - newser.com
Relmada Therapeutics (NASDAQ:RLMD) Trading 1.2% Higher – Here’s Why - Defense World
Relmada Therapeutics (NASDAQ:RLMD) Trading 1.2% HigherHere's Why - MarketBeat
Relmada Therapeutics Inc Stock (RLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Relmada Therapeutics Inc Stock (RLMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 26 '25 |
Buy |
0.62 |
80,545 |
49,938 |
814,569 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 28 '25 |
Buy |
0.74 |
55,976 |
41,422 |
1,000,000 |
| Kelly Paul Edward | Chief Operating Officer |
May 16 '25 |
Buy |
0.43 |
200,000 |
86,060 |
412,295 |
| Shenouda Maged | Chief Financial Officer |
May 19 '25 |
Buy |
0.49 |
90,000 |
43,686 |
228,335 |
| Shenouda Maged | Chief Financial Officer |
May 20 '25 |
Buy |
0.52 |
60,000 |
31,422 |
288,335 |
| Shenouda Maged | Chief Financial Officer |
May 16 '25 |
Buy |
0.44 |
50,000 |
22,100 |
138,335 |
| Ence Chuck | CA and CO |
May 16 '25 |
Buy |
0.45 |
228,961 |
103,330 |
267,931 |
| TRAVERSA SERGIO | Chief Executive Officer |
May 20 '25 |
Buy |
0.56 |
147,686 |
82,246 |
734,024 |
| TRAVERSA SERGIO | Chief Executive Officer |
May 16 '25 |
Buy |
0.45 |
172,314 |
77,472 |
556,338 |
| TRAVERSA SERGIO | Chief Executive Officer |
May 19 '25 |
Buy |
0.50 |
30,000 |
14,994 |
586,338 |
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):